Search
Proteomics managing director Richard Lipscombe.

WA science firm in China deal

Nedlands company Proteomics International Laboratories is hoping for increased support for its initial public offering after finalising an agreement with a Chinese drug development business.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
293rdProteomics International Laboratories29%0%
547thOrthocell-11%0%
643rdEphraim Resources-28%2%
750thResApp Health-54%132%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

16/04/18
$0 Other
16/04/18
$0 Other
06/04/18
$0 Issued
Total value as at the date of the transaction
Source: Morningstar

Revenue

130th↓Proteomics International Laboratories$1.8m
143rd-MOKO Social Media$1.2m
144th↑ResApp Health$1.1m
146th↑Ephraim Resources$1.1m
148th↓Orthocell$1.0m
239 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from Proteomics International Laboratories

374thRichard Lipscombe$325k
1103rdJohn Dunlop$67k
1182ndTerry Sweet$55k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer